Abstract
Summary. This literature review summarizes the results of studies on the use of anti-VEGF therapy with ranibizumab and aflibercept for the treatment of macular diseases (including neovascular age-related macular degeneration, diabetic retinal lesions, macular edema due to retinal vein occlusion, and myopic choroidal neovascularization) in routine clinical practice (RCP) in Russia. The data confirming the possibility of achieving favorable short-term and long-term outcomes of the method application in RCP are presented. Original ways to improve its effectiveness and safety based on data exploration of the quality of life features, adherence to treatment and treatment satisfaction of patients, taking into account clinical and organizational aspects of the use of anti-VEGF therapy, are proposed. Key words: anti-VEGF therapy; ranibizumab; aflibercept; routine clinical practice; long-term results; efficacy; safety
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
